BioTheryX Stock

BioTheryX is a clinical-stage biopharmaceutical company that focuses on the development of therapies for hematological malignancies.

Sign up today and learn more about BioTheryX Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About BioTheryX Stock

BioTheryX focuses on the development of therapies for hematological malignancies. It intends to leverage its extensive experience and proven commercial success to deliver efficacious therapies to patients with unmet medical needs more quickly and less expensively than the biomedical industry traditionally can and does. To do so, they are exploiting enhanced biology-driven models to identify effective core molecules that can be rapidly exploited using focused and prioritized chemistry approaches coupled with clinically proven translational approaches targeted for cancer and immune dysfunction. The company was founded in 2007 and is headquartered in Chappaqua, New York.

Funding History

June 2014$1.0M
September 2014$150K
May 2015$500K
July 2020$35.0M
May 2021$18.0M
May 2021$92.0M


Chief Business Officer

Sahm Nasseri

Chief Financial Officer

Jeff Caravella

Co-Founder, President & Board Member

Lawrence Zaslow

Co-Founder, Chief Development Officer & Chairman & Owner

David Stirling

Board Member

Robert Platek

Chief Executive Officer

Philippe Drouet


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: